Author contributions
Aswanth Reddy contributed to the preparation of the manuscript, writing
the initial draft, and finalizing the final draft. The author has given
final approval for the version to be published. The author agrees to be
accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part are appropriately
investigated and resolved.
Nkolika Nwankwo contributed to the preparation of the manuscript,
writing the initial draft, and finalizing the final draft. The author
has given final approval for the version to be published. The author
agrees to be accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part are
appropriately investigated and resolved.
Arjun Sekar contributed to the preparation of the manuscript, writing
the initial draft, and finalizing the final draft. The author has given
final approval for the version to be published. The author agrees to be
accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part are appropriately
investigated and resolved.
Aswini Kumar contributed to the preparation of the manuscript, writing
the initial draft, and finalizing the final draft. The author has given
final approval for the version to be published. The author agrees to be
accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part are appropriately
investigated and resolved.
References
1. Schiller LR, Pardi DS, Sellin JH. Chronic Diarrhea: Diagnosis and
Management. Clin Gastroenterol Hepatol. 2017 Feb;15(2):182-193.e3.
2. Burgers K, Lindberg B, Bevis ZJ. Chronic Diarrhea in Adults:
Evaluation and Differential Diagnosis. Am Fam Physician. 2020 Apr
15;101(8):472-480.
3. Gómez-Escudero O, Remes-Troche JM. Approach to the adult patient with
chronic diarrhea: A literature review. Rev Gastroenterol Mex (Engl Ed).
2021 Oct-Dec;86(4):387-402.
4. Camilleri M, Sellin JH, Barrett KE. Pathophysiology, Evaluation, and
Management of Chronic Watery Diarrhea. Gastroenterology. 2017
Feb;152(3):515-532.e2.
5. Thielman NM, Guerrant RL. Clinical practice. Acute infectious
diarrhea. N Engl J Med. 2004 Jan 1;350(1):38-47.
6. Wells SA Jr, Asa SL, Dralle H et al. American Thyroid Association
Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American
Thyroid Association guidelines for the management of medullary thyroid
carcinoma. Thyroid. 2015 Jun;25(6):567-610.
7. Roy M, Chen H, Sippel RS. Current understanding and management of
medullary thyroid cancer. Oncologist. 2013;18(10):1093-100.
8. Chen H, Sippel RS, O’Dorisio MS et al. North American Neuroendocrine
Tumor Society (NANETS). The North American Neuroendocrine Tumor Society
consensus guideline for the diagnosis and management of neuroendocrine
tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer.
Pancreas. 2010 Aug;39(6):775-83.
9. Thomas CM, Asa SL, Ezzat S et al. Diagnosis and pathologic
characteristics of medullary thyroid carcinoma-review of current
guidelines. Curr Oncol. 2019 Oct;26(5):338-344.
10. Pellegriti G, Leboulleux S, Baudin E et al. Long-term outcome of
medullary thyroid carcinoma in patients with normal postoperative
medical imaging. Br J Cancer. 2003 May 19;88(10):1537-42.
11. Pacini F, Castagna MG, Brilli L et al. ESMO Guidelines Working
Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v214-9.
12. Pusztaszeri MP, Bongiovanni M, Faquin WC. Update on the cytologic
and molecular features of medullary thyroid carcinoma. Adv Anat Pathol.
2014 Jan;21(1):26-35.
13. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of
remission in medullary thyroid carcinoma according to basal calcitonin
level. J Clin Endocrinol Metab. 2005 Apr;90(4):2029-34.
14. Tran K, Khan S, Taghizadehasl M et al. Gallium-68 Dotatate PET/CT is
superior to other imaging modalities in the detection of medullary
carcinoma of the thyroid in the presence of high serum calcitonin. Hell
J Nucl Med. 2015 Jan-Apr;18(1):19-24.
15. Ciampi R, Romei C, Ramone T et al. Genetic Landscape of Somatic
Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas
Studied by Next-Generation Targeted Sequencing. iScience. 2019 Oct
25;20:324-336.
16. Wells SA Jr, Robinson BG, Gagel RF et al. Vandetanib in patients
with locally advanced or metastatic medullary thyroid cancer: a
randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan
10;30(2):134-41. Erratum in: J Clin Oncol. 2013 Aug 20;31(24):3049.
17. Elisei R, Schlumberger MJ, Müller SP et al. Cabozantinib in
progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct
10;31(29):3639-46. Sep 3. Erratum in: J Clin Oncol. 2014 Jun
10;32(17):1864.
18. Schlumberger M, Jarzab B, Cabanillas ME et al. A Phase II Trial of
the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in
Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan
1;22(1):44-53.
19. Wirth LJ, Sherman E, Robinson B et al. Efficacy of Selpercatinib in
RET-Altered Thyroid Cancers. N Engl J Med. 2020 Aug 27;383(9):825-835.
20. Subbiah V, Hu MI, Wirth LJ et al. Pralsetinib for patients with
advanced or metastatic RET-altered thyroid cancer (ARROW): a
multi-cohort, open-label, registrational, phase 1/2 study. Lancet
Diabetes Endocrinol. 2021 Aug;9(8):491-501. doi:
10.1016/S2213-8587(21)00120-0. Epub 2021 Jun 9. Erratum in: Lancet
Diabetes Endocrinol. 2021 Oct;9(10):e4.
21.Pais MC, Maia T, Peixoto A et al. Diarrhea as a form of presentation
of medullary thyroid carcinoma. Porto Biomed J. 2018 Jul 3;3(3):e18.